{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:05:49Z","timestamp":1786982749724,"version":"build-2736575974"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T00:00:00Z","timestamp":1769472000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T00:00:00Z","timestamp":1769472000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","award":["Grant No. 91973623"],"award-info":[{"award-number":["Grant No. 91973623"]}],"id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s40257-025-01004-z","type":"journal-article","created":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T10:00:14Z","timestamp":1769508014000},"page":"401-410","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Long-Term Real-World Evaluation of Abrocitinib in Moderate-to-Severe Atopic Dermatitis Across a Diverse Patient Population in a Multi-site Hospital System"],"prefix":"10.1007","volume":"27","author":[{"given":"Megan","family":"Lau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Largen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasmine","family":"Levine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ester","family":"Del Duca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lillian","family":"Mo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn Jayne","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akbobek","family":"Amangeldiyeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel Correa","family":"da Rosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Princess","family":"Edemobi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Ungar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9363-324X","authenticated-orcid":false,"given":"Emma","family":"Guttman-Yassky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,27]]},"reference":[{"issue":"8 Suppl.","key":"1004_CR1","first-page":"S115","volume":"23","author":"C Avena-Woods","year":"2017","unstructured":"Avena-Woods C. Overview of atopic dermatitis. Am J Manag Care. 2017;23(8 Suppl.):S115\u201323.","journal-title":"Am J Manag Care"},{"key":"1004_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/j.1365-2230.2012.04336.x","volume":"Suppl. 1","author":"SE Baron","year":"2012","unstructured":"Baron SE, Cohen SN, Archer CB. Guidance on the diagnosis and clinical management of atopic eczema: diagnosis and clinical management of atopic eczema. Clin Exp Dermatol. 2012;Suppl. 1:7\u201312. https:\/\/doi.org\/10.1111\/j.1365-2230.2012.04336.x.","journal-title":"Clin Exp Dermatol"},{"issue":"1","key":"1004_CR3","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1093\/bjd\/ljad339","volume":"190","author":"J Tian","year":"2023","unstructured":"Tian J, Zhang D, Yang Y, et al. Global epidemiology of atopic dermatitis: a\u00a0comprehensive systematic analysis and modelling study. Br J Dermatol. 2023;190(1):55\u201361. https:\/\/doi.org\/10.1093\/bjd\/ljad339.","journal-title":"Br J Dermatol"},{"issue":"12","key":"1004_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/children6120133","volume":"6","author":"CH Na","year":"2019","unstructured":"Na CH, Chung J, Simpson EL. Quality of life and disease impact of atopic dermatitis and psoriasis on children and their families. Children Basel. 2019;6(12):133. https:\/\/doi.org\/10.3390\/children6120133.","journal-title":"Children Basel"},{"issue":"5","key":"1004_CR5","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1038\/s41423-023-00992-4","volume":"20","author":"P Facheris","year":"2023","unstructured":"Facheris P, Jeffery J, Del Duca E, Guttman-Yassky E. The translational revolution in atopic dermatitis: the paradigm shift from pathogenesis to treatment. Cell Mol Immunol. 2023;20(5):448\u201374. https:\/\/doi.org\/10.1038\/s41423-023-00992-4.","journal-title":"Cell Mol Immunol"},{"issue":"11","key":"1004_CR6","doi-asserted-by":"publisher","first-page":"2927","DOI":"10.3390\/biomedicines10112927","volume":"10","author":"F Lobefaro","year":"2022","unstructured":"Lobefaro F, Gualdi G, Di Nuzzo S, Amerio P. Atopic dermatitis: clinical aspects and unmet needs. Biomedicines. 2022;10(11):2927. https:\/\/doi.org\/10.3390\/biomedicines10112927.","journal-title":"Biomedicines"},{"issue":"1","key":"1004_CR7","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1177\/10600280221096713","volume":"57","author":"PO Perche","year":"2023","unstructured":"Perche PO, Cook MK, Feldman SR. Abrocitinib: a new FDA-approved drug for moderate-to-severe atopic dermatitis. Ann Pharmacother. 2023;57(1):86\u201398. https:\/\/doi.org\/10.1177\/10600280221096713.","journal-title":"Ann Pharmacother"},{"issue":"18","key":"1004_CR8","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1007\/s40265-021-01638-3","volume":"81","author":"ED Deeks","year":"2021","unstructured":"Deeks ED, Duggan S. Abrocitinib: first approval. Drugs. 2021;81(18):2149\u201357. https:\/\/doi.org\/10.1007\/s40265-021-01638-3.","journal-title":"Drugs"},{"issue":"10","key":"1004_CR9","doi-asserted-by":"publisher","first-page":"2056","DOI":"10.1111\/jdv.19280","volume":"37","author":"K Reich","year":"2023","unstructured":"Reich K, Silverberg JI, Papp KA, et al. Abrocitinib efficacy and safety in patients with moderate\u2010to\u2010severe atopic dermatitis: results from phase 3 studies, including the long\u2010term extension JADE EXTEND study. J Eur Acad Dermatol Venereol. 2023;37(10):2056\u201366. https:\/\/doi.org\/10.1111\/jdv.19280.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"1004_CR10","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1007\/s40257-023-00785-5","volume":"24","author":"EL Simpson","year":"2023","unstructured":"Simpson EL, Silverberg JI, Thyssen JP, et al. Efficacy and safety of abrocitinib in patients with severe and\/or difficult-to-treat atopic dermatitis: a post hoc analysis of the randomized phase 3 JADE COMPARE trial. Am J Clin Dermatol. 2023;24(4):609\u201321. https:\/\/doi.org\/10.1007\/s40257-023-00785-5.","journal-title":"Am J Clin Dermatol"},{"issue":"4","key":"1004_CR11","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1016\/j.jaad.2024.05.081","volume":"91","author":"S Keow","year":"2024","unstructured":"Keow S, Abu-Hilal M. Effectiveness of abrocitinib for the treatment of moderate-to-severe atopic dermatitis in patients switched from dupilumab and\/or tralokinumab: a real-world retrospective study. J Am Acad Dermatol. 2024;91(4):734\u20135. https:\/\/doi.org\/10.1016\/j.jaad.2024.05.081.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"1004_CR12","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2024.2411855","volume":"35","author":"L Gargiulo","year":"2024","unstructured":"Gargiulo L, Ibba L, Alfano A, et al. Short-term effectiveness and safety of abrocitinib in adults with moderate-to-severe atopic dermatitis: results from a 16-week real-world multicenter retrospective study\u2014il AD (Italian landscape atopic dermatitis). J Dermatolog Treat. 2024;35(1):2411855. https:\/\/doi.org\/10.1080\/09546634.2024.2411855.","journal-title":"J Dermatolog Treat"},{"issue":"2","key":"1004_CR13","doi-asserted-by":"publisher","first-page":"385","DOI":"10.3390\/pharmaceutics15020385","volume":"15","author":"H Iznardo","year":"2023","unstructured":"Iznardo H, Ro\u00e9 E, Serra-Baldrich E, Puig L. Efficacy and safety of JAK1 inhibitor abrocitinib in atopic dermatitis. Pharmaceutics. 2023;15(2):385. https:\/\/doi.org\/10.3390\/pharmaceutics15020385.","journal-title":"Pharmaceutics"},{"issue":"8","key":"1004_CR14","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1001\/jamadermatol.2020.1406","volume":"156","author":"JI Silverberg","year":"2020","unstructured":"Silverberg JI, Simpson EL, Thyssen JP, et al. Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2020;156(8):863\u201373. https:\/\/doi.org\/10.1001\/jamadermatol.2020.1406.","journal-title":"JAMA Dermatol"},{"issue":"12","key":"1004_CR15","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1111\/jdv.19378","volume":"37","author":"JI Olydam","year":"2023","unstructured":"Olydam JI, Schl\u00f6sser AR, Custurone P, Nijsten TEC, Hijnen D. Real\u2010world effectiveness of abrocitinib treatment in patients with difficult\u2010to\u2010treat atopic dermatitis. J Eur Acad Dermatol Venereol. 2023;37(12):2537\u201342. https:\/\/doi.org\/10.1111\/jdv.19378.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"1004_CR16","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1111\/all.16495","volume":"80","author":"Z Li","year":"2025","unstructured":"Li Z, Wang Y, Wu Y, et al. Real-world efficacy and safety of abrocitinib in Chinese atopic dermatitis patients: a single-center prospective study. Allergy. 2025;80(5):1417\u201327. https:\/\/doi.org\/10.1111\/all.16495.","journal-title":"Allergy"},{"issue":"2","key":"1004_CR17","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.jaad.2022.04.009","volume":"87","author":"VY Shi","year":"2022","unstructured":"Shi VY, Bhutani T, Fonacier L, et al. Phase 3 efficacy and safety of abrocitinib in adults with moderate-to-severe atopic dermatitis after switching from dupilumab (JADE EXTEND). J Am Acad Dermatol. 2022;87(2):351\u20138. https:\/\/doi.org\/10.1016\/j.jaad.2022.04.009.","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"1004_CR18","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1093\/ced\/llaf144","volume":"50","author":"L Ibba","year":"2025","unstructured":"Ibba L, Gargiulo L, Bianco M, et al. Potential role of leptin in Janus kinase 2 inhibitor-associated weight gain: a monocentric retrospective study. Clin Exp Dermatol. 2025;50(9):1834\u20137. https:\/\/doi.org\/10.1093\/ced\/llaf144.","journal-title":"Clin Exp Dermatol"},{"issue":"11","key":"1004_CR19","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1136\/ard-2022-222405","volume":"81","author":"AR Balanescu","year":"2022","unstructured":"Balanescu AR, Citera G, Pascual-Ramos V, et al. Infections in patients with rheumatoid arthritis receiving tofacitinib versus tumour necrosis factor inhibitors: results from the open-label, randomised controlled ORAL surveillance trial. Ann Rheum Dis. 2022;81(11):1491\u2013503. https:\/\/doi.org\/10.1136\/ard-2022-222405.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"1004_CR20","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1016\/j.jaip.2025.02.040","volume":"13","author":"MJ Cork","year":"2025","unstructured":"Cork MJ, Deleuran M, Geng B, et al. Long-term safety of abrocitinib in moderate-to-severe atopic dermatitis: integrated analysis by age. J Allergy Clin Immunol Pract. 2025;13(5):1164-75.e2. https:\/\/doi.org\/10.1016\/j.jaip.2025.02.040.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"7","key":"1004_CR21","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1002\/psp4.12419","volume":"8","author":"S Koride","year":"2019","unstructured":"Koride S, Nayak S, Banfield C, Peterson MC. Evaluating the role of Janus kinase pathways in platelet homeostasis using a systems modeling approach. CPT Pharmacometrics Syst Pharmacol. 2019;8(7):478\u201388. https:\/\/doi.org\/10.1002\/psp4.12419.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"1","key":"1004_CR22","first-page":"29","volume":"19","author":"TR Ulich","year":"1991","unstructured":"Ulich TR, del Castillo J, Yin SM, Egrie JC. The erythropoietic effects of interleukin 6 and erythropoietin in vivo. Exp Hematol. 1991;19(1):29\u201334.","journal-title":"Exp Hematol"},{"issue":"1","key":"1004_CR23","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/s1549-3741(04)30001-8","volume":"30","author":"JD Rozich","year":"2004","unstructured":"Rozich JD, Howard RJ, Justeson JM, Macken PD, Lindsay ME, Resar RK. Standardization as a mechanism to improve safety in health care. Jt Comm J Qual Saf. 2004;30(1):5\u201314. https:\/\/doi.org\/10.1016\/s1549-3741(04)30001-8.","journal-title":"Jt Comm J Qual Saf"},{"issue":"5","key":"1004_CR24","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1016\/j.jaip.2023.02.005","volume":"11","author":"EH van den Bogaard","year":"2023","unstructured":"van den Bogaard EH, Elias PM, Goleva E, et al. Targeting skin barrier function in atopic dermatitis. J Allergy Clin Immunol Pract. 2023;11(5):1335\u201346. https:\/\/doi.org\/10.1016\/j.jaip.2023.02.005.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"2","key":"1004_CR25","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.jaad.2023.04.011","volume":"89","author":"J Mineroff","year":"2023","unstructured":"Mineroff J, Nguyen JK, Jagdeo J. Racial and ethnic underrepresentation in dermatology clinical trials. J Am Acad Dermatol. 2023;89(2):293\u2013300. https:\/\/doi.org\/10.1016\/j.jaad.2023.04.011.","journal-title":"J Am Acad Dermatol"}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-025-01004-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-025-01004-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-025-01004-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T11:19:51Z","timestamp":1774696791000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40257-025-01004-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,27]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["1004"],"URL":"https:\/\/doi.org\/10.1007\/s40257-025-01004-z","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,27]]},"assertion":[{"value":"31 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Emma Guttman-Yassky is an employee of Mount Sinai and has received research grants from and\/or is a consultant for AbbVie, Arcutis, Almirall, Amgen, AnaptysBio, Apogee Therapeutics, Apollo Therapeutics Limited, Artax Biopharma Inc., Aslan, Astria, Bristol Meyers Squibb, Boerhinger-Ingelhiem, Calliditas, Cara Therapeutics, Celldex, Centrexion Therapeutics Corporation, Concert, Connect Biopharm, Coty, DBV Technologies, Eli Lilly, Enveda Biosciences, Escient Pharmaceuticals, Inc., Fairmount Funds Management LLC, FL2022-001, Inc., Galderma, Gate Bio, Google Ventures (GV), GSK Immunology, Incyte, Inmagene, Janssen Biotech, Jasper Therapeutics, Kymera Therapeutics, Kyowa Kirin, Leo Pharma, Matchpoint Therapeutics, Merck, Nektar Therapeutics, Novartis Pharmaceuticals, NUMAB Therapeutics AG, Nuvig, OrbiMed Advisors LLC, OTSUKA, Pfizer, Pharmaxis Ltd, Pioneering Medicine VII, Inc., Proteologix US Inc, Q32Bio, RAPT, RayThera, Inc, Regeneron Pharmaceuticals, RibonTherapeutics, Inc., Rocatinlimab, SAGIMET Bioscieces, Sanofi, SATO, Schr\u00f6dinger, Inc., Sitryx, Sun Pharma Advanced Research Company (SPARC), Takeda, Teva Branded Pharmaceutical Products R&D, Inc, TRex, UCB, and Ventyx Biosyences. Benjamin Ungar is an employee of Mount Sinai and has received research funds (grants paid to the institution) from\u00a0Bristol Myers Squibb, Incyte, Rapt Therapeutics, Pfizer, and Sanofi. He is also a consultant for AbbVie, Arcutis Biotherapeutics, Bristol Myers Squibb, Botanix Pharmaceuticals, Castle Biosciences, Ebla Holdco, Fresenius Kabi, Galderma, J&J, Leo Pharma, Lilly, Pfizer, Primus Pharmaceuticals, Sanofi, and UCB. Megan Lau, Joseph Largen, Jasmine Levine, Ester Del Duca, Lillian Mo, Kathryn Jayne Tan\n                      ,\n                      Daniel Liu, Akbobek Amangeldiyeva, Joel Correa da Rosa, and Princess Edemobi have no conflicts of interest that are directly relevant to the content of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"The Institutional Review Board of the Icahn School of Medicine at Mount Sinai approved the study (Protocol No. STUDY-24-00712).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"De-identified data may be made available from the corresponding author upon reasonable request, contingent on approval from the Institutional Review Board of the Icahn School of Medicine at Mount Sinai (Protocol No. STUDY-24-00712).","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Conceptualization: EG-Y and BU; methodology: EG-Y and BU; formal analysis: ML, EDD, LM, KJT, DL, AA, and JCdR; investigation: JL, JLe, LM; writing (original draft preparation): ML; writing (review and editing): ML, EDD, LM, KJT, DL, BU, and EG-Y; resources: JL, JLe, LM, and PE; supervision: EG-Y.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}